labiotech1d
Top biotech deals of September 2024
Discover the major biotech partnerships, collaborations and mergers and acquisitions that made headlines in September 2024.
labiotech1d
How an innovative, data-driven approach is revolutionizing drug discovery for solid tumors
Learn how cancer tissue biobanks and insights into solid tumor heterogeneity are transforming drug discovery and leading to ...
labiotech2d
Spinal cord injury: Are we getting closer to a treatment?
Explore innovative treatments for spinal cord injury in clinical trials, including Lineage's OPC1 and NervGen's NVG-291, ...
labiotech6d
Six biotechs driving progress in Duchenne muscular dystrophy
Discover six innovative clinical-stage biotech companies fostering R&D in the Duchenne muscular dystrophy therapeutic space.
labiotech5d
The biggest private biotech investments in September 2024
The companies Candid Therapeutics, ArsenalBio, and eGenesis bagged the biggest private biotech investments in September 2024.
labiotech7d
Resolution Therapeutics raises $85 million to advance its macrophage therapy
A week after Vicebio’s $100 million series B round, another U.K.-based biotech makes the headlines. Today, Resolution Therapeutics, a clinical-stage biotech company, secured $85 million (£63.5 million ...